Urologie pro praxi 3/2003
Benigní hyperplazie prostaty a hypertenze
Benign hyperplasia of prostate gland and hypertension Benign hyperplasia of prostate gland (BHP) occurs frequently in conjunction with hypertension (HTN). By estimation, 40% of men with symptoms from lower urinary tract caused by BHP suffer in parallel from some form of HTN. It is not clear now, whether this finding means a comorbidity by a mere chance by incidence of BHP and HTN in men of 60 years and older, or if there are some common etiopathogenetic processes and whether an impact into a one of mentioned disorders can influence the course of other one. In both of diseases, there is a high activity of alfa-1 adrenergic receptors (alfa-1 AR) described, which leads to elevated peripheral vasoconstriction (in patients with hypertension) and to excessive stimulation of alfa-1 AR in region of cervix of urinary bladder, prostate and urethra (in BHP). The etiology of both BHP and essential hypertension is unknown, and therefore we are not able to treat causally and cure them. Many men live with the decompensation of BHP and untreated HTN (by estimation 20%), a high percentage of men undergo therapy of BHP and HTN, which is not in concordance with the current scientific knowledge (for example at least 35% of hypertensive men from 58 million patients in the USA are not being followed up and treated sufficiently). Pharmacologists disagree whether to treat both diseases by one sort of a drug provided, that this drug is not the first or second choice of treatment at least in one of the diseases. Therefore the role of alfa-1AR blockers suitable for therapy of BHP and HTN remain opened question for pharmacologists, urologists and cardiologists. Key words: benign prostatic hyperplasia, hypertension.
